NO2970236T3 - - Google Patents

Info

Publication number
NO2970236T3
NO2970236T3 NO14715427A NO14715427A NO2970236T3 NO 2970236 T3 NO2970236 T3 NO 2970236T3 NO 14715427 A NO14715427 A NO 14715427A NO 14715427 A NO14715427 A NO 14715427A NO 2970236 T3 NO2970236 T3 NO 2970236T3
Authority
NO
Norway
Application number
NO14715427A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2970236T3 publication Critical patent/NO2970236T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO14715427A 2013-03-15 2014-03-14 NO2970236T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
EP14715427.2A EP2970236B1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (1)

Publication Number Publication Date
NO2970236T3 true NO2970236T3 (cg-RX-API-DMAC10.html) 2018-01-27

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14715427A NO2970236T3 (cg-RX-API-DMAC10.html) 2013-03-15 2014-03-14

Country Status (33)

Country Link
US (1) US9617250B2 (cg-RX-API-DMAC10.html)
EP (1) EP2970236B1 (cg-RX-API-DMAC10.html)
JP (1) JP6387361B2 (cg-RX-API-DMAC10.html)
KR (1) KR102212975B1 (cg-RX-API-DMAC10.html)
CN (1) CN105189487B (cg-RX-API-DMAC10.html)
AR (1) AR095523A1 (cg-RX-API-DMAC10.html)
AU (1) AU2014229217B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015023161B1 (cg-RX-API-DMAC10.html)
CA (1) CA2900910C (cg-RX-API-DMAC10.html)
CL (1) CL2015002620A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119619T1 (cg-RX-API-DMAC10.html)
DK (1) DK2970236T3 (cg-RX-API-DMAC10.html)
EA (1) EA029309B1 (cg-RX-API-DMAC10.html)
ES (1) ES2649475T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171763T1 (cg-RX-API-DMAC10.html)
HU (1) HUE035154T2 (cg-RX-API-DMAC10.html)
IL (1) IL241363B (cg-RX-API-DMAC10.html)
LT (1) LT2970236T (cg-RX-API-DMAC10.html)
MA (1) MA38482B1 (cg-RX-API-DMAC10.html)
MX (1) MX363545B (cg-RX-API-DMAC10.html)
MY (1) MY173573A (cg-RX-API-DMAC10.html)
NO (1) NO2970236T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ713080A (cg-RX-API-DMAC10.html)
PH (1) PH12015502118A1 (cg-RX-API-DMAC10.html)
PL (1) PL2970236T3 (cg-RX-API-DMAC10.html)
PT (1) PT2970236T (cg-RX-API-DMAC10.html)
SA (1) SA515361104B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201507227UA (cg-RX-API-DMAC10.html)
SI (1) SI2970236T1 (cg-RX-API-DMAC10.html)
TW (1) TWI623534B (cg-RX-API-DMAC10.html)
UA (1) UA115357C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014141171A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201507657B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
JP5253401B2 (ja) * 2006-09-07 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド 免疫調節薬としてのピリジン−4−イル誘導体
CL2007002594A1 (es) 2006-09-08 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
CA2662673A1 (en) 2006-09-21 2008-03-27 Martin Bolli Phenyl derivatives and their use as immunomodulators
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
EP2195311B1 (en) 2007-08-17 2011-03-23 Actelion Pharmaceuticals Ltd. Pyridine derivatives as s1p1/edg1 receptor modulators
CN101970420B (zh) 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CN101965345B (zh) 2008-03-06 2014-05-28 埃科特莱茵药品有限公司 吡啶化合物
EP2262800A1 (en) 2008-03-06 2010-12-22 Actelion Pharmaceuticals Ltd. Novel pyrimidine-pyridine derivatives
JP5435745B2 (ja) 2008-03-07 2014-03-05 アクテリオン ファーマシューティカルズ リミテッド 免疫調節剤としてのピリジン−2−イル誘導体
MX2010009645A (es) 2008-03-07 2010-09-28 Actelion Pharmaceuticals Ltd Derivados novedosos de aminometil benceno.
PT2291080E (pt) * 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
EP2403849B1 (en) 2009-03-03 2014-07-16 Merck Serono S.A. Oxazole pyridine derivatives useful as S1P1 receptor agonists
TWI410421B (zh) 2009-07-16 2013-10-01 Actelion Pharmaceuticals Ltd 吡啶-4-基衍生物
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
CA2818470C (en) 2011-01-19 2019-03-05 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives

Also Published As

Publication number Publication date
EA029309B1 (ru) 2018-03-30
MY173573A (en) 2020-02-04
MA38482B1 (fr) 2018-11-30
CY1119619T1 (el) 2018-04-04
CN105189487B (zh) 2017-12-26
PT2970236T (pt) 2017-11-30
CL2015002620A1 (es) 2016-03-18
CA2900910C (en) 2021-03-30
MA38482A1 (fr) 2017-12-29
BR112015023161A2 (pt) 2017-07-18
HRP20171763T1 (hr) 2017-12-29
WO2014141171A1 (en) 2014-09-18
KR20150128947A (ko) 2015-11-18
BR112015023161B1 (pt) 2022-11-16
IL241363A0 (en) 2015-11-30
TWI623534B (zh) 2018-05-11
AU2014229217B2 (en) 2017-12-14
MX2015012293A (es) 2015-12-16
IL241363B (en) 2018-11-29
US9617250B2 (en) 2017-04-11
JP2016512227A (ja) 2016-04-25
BR112015023161A8 (pt) 2021-06-22
DK2970236T3 (en) 2017-10-16
CN105189487A (zh) 2015-12-23
MX363545B (es) 2019-03-27
SG11201507227UA (en) 2015-10-29
SA515361104B1 (ar) 2016-06-28
EP2970236A1 (en) 2016-01-20
SI2970236T1 (sl) 2017-11-30
AU2014229217A1 (en) 2015-11-05
UA115357C2 (uk) 2017-10-25
EP2970236B1 (en) 2017-08-30
TW201443044A (zh) 2014-11-16
HK1220454A1 (en) 2017-05-05
AR095523A1 (es) 2015-10-21
PH12015502118B1 (en) 2016-01-25
US20160031866A1 (en) 2016-02-04
KR102212975B1 (ko) 2021-02-05
LT2970236T (lt) 2017-11-10
JP6387361B2 (ja) 2018-09-05
PH12015502118A1 (en) 2016-01-25
CA2900910A1 (en) 2014-09-18
ZA201507657B (en) 2022-08-31
ES2649475T3 (es) 2018-01-12
HUE035154T2 (en) 2018-05-02
NZ713080A (en) 2020-06-26
EA201500931A1 (ru) 2016-03-31
PL2970236T3 (pl) 2018-01-31

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cg-RX-API-DMAC10.html)
BR112016008849A2 (cg-RX-API-DMAC10.html)
BR112015007533A2 (cg-RX-API-DMAC10.html)
BR102016010778A2 (cg-RX-API-DMAC10.html)
BR112014017733A2 (cg-RX-API-DMAC10.html)
BR112014017739A2 (cg-RX-API-DMAC10.html)
BR112014018502A2 (cg-RX-API-DMAC10.html)
BR112014018516A2 (cg-RX-API-DMAC10.html)
BR112014017765A2 (cg-RX-API-DMAC10.html)
BR112014018480A2 (cg-RX-API-DMAC10.html)
BR112014017855A2 (cg-RX-API-DMAC10.html)
BR112014020341A2 (cg-RX-API-DMAC10.html)
BR112016012711A2 (cg-RX-API-DMAC10.html)
BR112016011312A2 (cg-RX-API-DMAC10.html)
BR112016012759A2 (cg-RX-API-DMAC10.html)
BR112016009279A2 (cg-RX-API-DMAC10.html)
BR112014017901A2 (cg-RX-API-DMAC10.html)
BR112014017722A2 (cg-RX-API-DMAC10.html)
BR112016001458A2 (cg-RX-API-DMAC10.html)
BR112014018578A2 (cg-RX-API-DMAC10.html)
BR112014017601A2 (cg-RX-API-DMAC10.html)
BR112015015312A2 (cg-RX-API-DMAC10.html)
BR112014024039A2 (cg-RX-API-DMAC10.html)
BR112014018496A2 (cg-RX-API-DMAC10.html)
BR112014018514A2 (cg-RX-API-DMAC10.html)